PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions
about
The Dual Roles of MYC in Genomic Instability and Cancer ChemoresistancePathogenesis and heterogeneity of ovarian cancer.PARP Inhibitors in Reproductive System Cancers: Current Use and Developments.Ovarian cancer stem cells: still an elusive entity?The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast CancerRucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer.The role of membrane transporters in ovarian cancer chemoresistance and prognosis.Relationship Between the Expression of O6-Methylguanine-DNA Methyltransferase (MGMT) and p53, and the Clinical Response in Metastatic Pancreatic Adenocarcinoma Treated with FOLFIRINOX.Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.Base excision repair of oxidative DNA damage: from mechanism to disease.Prediction of therapy response in ovarian cancer: Where are we now?The role of biomarkers in the management of epithelial ovarian cancer.The safety of antiangiogenic agents and PARP inhibitors in platinum-sensitive recurrent ovarian cancer.The potential role of miRNAs in therapy of breast and ovarian cancers associated with BRCA1 mutation.Human Antibody Fusion Proteins/Antibody Drug Conjugates in Breast and Ovarian CancerRisk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials.SNPs near the cysteine proteinase cathepsin O gene (CTSO) determine tamoxifen sensitivity in ERα-positive breast cancer through regulation of BRCA1Novel DNA targeted therapies for head and neck cancers: clinical potential and biomarkers.Saccharomyces genome database informs human biology.When to Consider Risk-Reducing Mastectomy in BRCA1/BRCA2 Mutation Carriers with Advanced Stage Ovarian Cancer: a Case Study Illustrating the Genetic Counseling Challenges.Ancient and modern: hints of a core post-transcriptional network driving chemotherapy resistance in ovarian cancer.BRCA1 or CDK12 loss sensitizes cells to CHK1 inhibitors.A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer.Advances in ovarian cancer therapy.High Resolution Melting Analysis is Very Useful to Identify Breast Cancer Type 1 Susceptibility Protein (BRCA1) c.4964_4982del19 (rs80359876) Founder Calabrian Pathogenic Variant on Peripheral Blood and Buccal Swab DNA.Role of BRCA Mutations in the Modulation of Response to Platinum Therapy.A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers.Interference with DNA repair after ionizing radiation by a pyrrole-imidazole polyamide.Synthetic lethality in CCNE1-amplified high grade serous ovarian cancer through combined inhibition of Polo-like kinase 1 and microtubule dynamics.MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models.The Role of the Insulin-Like Growth Factor 1 Pathway in Immune Tumor Microenvironment and Its Clinical Ramifications in Gynecologic Malignancies.Recent Advances in the Treatment of Breast Cancer.Consensus report of the 8 and 9th Weinman Symposia on Gene x Environment Interaction in carcinogenesis: novel opportunities for precision medicine
P2860
Q33836799-92580584-3C16-4226-B3AB-B0F6B3C4B3A4Q37546692-8C86A0DA-E773-42DB-A67D-AFD636B62456Q37607283-E744C385-D132-458A-BC5A-9A4816899EDCQ37713683-A6B9AFF7-AB7C-45C4-BB91-D167D095DAE9Q37720246-65ABE31F-CF17-41A4-BF01-0CA1945846F9Q38645200-1325F867-F3D8-4EFF-A171-8EE97970F5CAQ38683064-CC3D27BD-2F40-46FA-88C0-AC58AF2C57EDQ38831157-7B2BE807-7A82-4694-B3C1-B6C74BCC9C4FQ38954348-65730265-1859-4DC0-B7D0-2634DB5F9651Q39136548-3D39A40D-EEB3-43D7-AF08-9CFE94EE40BEQ39263260-CF9FF9AC-9E13-4512-A7CD-0315607F7DDBQ39281140-8D06866C-0A53-4BE7-BE79-C92AC0785A08Q39282981-F69AB457-9E93-4A6E-A319-BE76D0E17EF2Q42368096-A4E08F35-6782-4E13-9EDF-905FD7999A89Q42660155-274DC9B2-B628-4ADA-BF6F-6C65B1443489Q42673155-7A72F599-192A-48F5-8F6F-FDB5D103C48DQ42703024-B17CA64E-8237-4BCF-A064-4B0955B7178DQ45790068-806E289C-1A1B-45EE-B1F7-5BF8612D6A53Q47096539-E3E207A6-89D8-4A35-8EA3-21675FC3709DQ47101331-7A932E8E-71EC-41B3-95EE-C7D2E2210CABQ47200415-98A5FC01-66FF-41AB-9219-54D5F3B579B6Q47660928-C975ACB5-DF94-429E-BE97-9A0CD68817B8Q47861842-A77FCB26-8624-48E4-864F-B3FA84D9A459Q48104995-5C6B39B4-68C3-4558-8995-2A65D9503605Q48844338-E75A646A-90A4-47B0-9F76-EF15AB73914AQ49829001-F87346A7-AE46-4066-A970-2093E8A24913Q52603963-0C9BD40D-6F45-4A4A-B214-4CA7E8A9882BQ52715168-5F462B3D-4729-4401-A63F-2079BCEA9E5CQ55054132-E6CDA1FB-4B7E-48A5-9DA4-F881E87AE1DAQ55105483-07A60BD2-A316-4BA3-9483-635D6EAA0727Q55220517-B20505C9-6525-40AA-8940-72906090D76CQ55353691-27752CDC-50D4-4B09-8B5C-867E2E2426E2Q57461758-949BA7B1-DCE0-417A-A6E1-BE7BDE899F38
P2860
PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions
description
2016 nî lūn-bûn
@nan
2016 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
PARP inhibitors for BRCA1/2-mu ...... practice and future directions
@ast
PARP inhibitors for BRCA1/2-mu ...... practice and future directions
@en
PARP inhibitors for BRCA1/2-mu ...... practice and future directions
@nl
type
label
PARP inhibitors for BRCA1/2-mu ...... practice and future directions
@ast
PARP inhibitors for BRCA1/2-mu ...... practice and future directions
@en
PARP inhibitors for BRCA1/2-mu ...... practice and future directions
@nl
prefLabel
PARP inhibitors for BRCA1/2-mu ...... practice and future directions
@ast
PARP inhibitors for BRCA1/2-mu ...... practice and future directions
@en
PARP inhibitors for BRCA1/2-mu ...... practice and future directions
@nl
P2860
P921
P3181
P356
P1476
PARP inhibitors for BRCA1/2-mu ...... practice and future directions
@en
P2093
G E Konecny
R S Kristeleit
P2860
P2888
P304
P3181
P356
10.1038/BJC.2016.311
P407
P5008
P577
2016-11-08T00:00:00Z
P6179
1029734186